Rules that exempt drugs from Medicare negotiation if there’s ‘meaningful’ generic competition could whittle down the effect of the program.
Big Pharma
Posted inHealth and Social Policy
Medicare Price Negotiation: Ten Drugs That Made the List, and Ten That Should Have
Advocates were thrilled that Medicare will negotiate the price of several insulins. But other high-profit drugs are protected by the new program’s rules.
Posted inHealth and Social Policy
Pricing a Lifesaving Drug
Will Medicare use its ample leverage to make Wegovy affordable?
Posted inMoney, Politics, and Power
Who’s Running Big Pharma’s Last Stand Against Slightly Fairer Drug Pricing
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short.
Posted inMoney, Politics, and Power
It’s All the Same Fight
Reflections on a week in the age of corporate power
Posted inLaw and Justice
An Unlikely Twist in Corporate Accountability
The Sacklers might actually get their legal immunity stripped, by the Supreme Court of all people.
Posted inTAP
Eminent Domain for Overpriced Drugs
Today on TAP: Exhibit A is the case of the EpiPen. It should cost a few dollars rather than the $600 or more charged by monopolist Viatris.
Posted inHealth and Social Policy
Gatekeeper of the Gougers
In a newly unsealed deposition, a former Express Scripts executive (unintentionally) reveals how hard his colleagues were undermining his ‘mission’ to cut drug prices.
Posted inHealth and Social Policy
The Oliver Twist
How orphan drugs became big business for Big Pharma
Posted inHealth and Social Policy
A Sick System
The business of health care in America is deeply out of whack.